Avon Launches ‘Kiss Goodbye to Breast Cancer’ Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

NEW YORK-This month Avon Products, Inc. launches Kiss Goodbye to Breast Cancer, a marketing program that includes a fundraising lipstick, grassroots outreach through a Day of Commitment (September 25), gala awards to be held October 9, and celebrity support from singer Christina Aguilera and tennis players Serena and Venus Williams, among others.

NEW YORK—This month Avon Products, Inc. launches Kiss Goodbye to Breast Cancer, a marketing program that includes a fundraising lipstick, grassroots outreach through a Day of Commitment (September 25), gala awards to be held October 9, and celebrity support from singer Christina Aguilera and tennis players Serena and Venus Williams, among others.

The goal of the program is to raise additional funds and public awareness for the fight against breast cancer, building on the more than $140 million that Avon has already raised globally between 1992 to the end of 2000.

The lipsticks, priced at an affordable $4.00, include six shades in the Avon Ultra Color Rich Renewable formulation, named to capture the spirit of the crusade: Courageous Spirit, Crusade Pink, Faithful Heart, Inspirational Life, Strength, and Triumph.

The entire Avon Breast Cancer Crusade "pink ribbon" collection is available through Avon independent sales representatives by calling 1-800-FOR-AVON or visiting www.avoncrusade.com.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.